Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model

M. Denorme, L. Yon, C. Roux, B.J. Gonzalez, E. Baudin, Y. Anouar, C. Dubessy

Open source

DOI
10.1016/j.canlet.2014.07.005
Published
2014-10
Container
Cancer Letters
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.canlet.2014.07.005,
  title = {Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model},
  author = {M. Denorme and L. Yon and C. Roux and B.J. Gonzalez and E. Baudin and Y. Anouar and C. Dubessy},
  year = {2014},
  journal = {Cancer Letters},
  doi = {10.1016/j.canlet.2014.07.005},
  url = {https://doi.org/10.1016/j.canlet.2014.07.005}
}

RIS

TY  - JOUR
TI  - Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model
AU  - M. Denorme
AU  - L. Yon
AU  - C. Roux
AU  - B.J. Gonzalez
AU  - E. Baudin
AU  - Y. Anouar
AU  - C. Dubessy
PY  - 2014
JO  - Cancer Letters
DO  - 10.1016/j.canlet.2014.07.005
UR  - https://doi.org/10.1016/j.canlet.2014.07.005
ER  - 

APA

Denorme, M., Yon, L., Roux, C., Gonzalez, B., Baudin, E., Anouar, Y., & Dubessy, C. (2014). Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model. Cancer Letters. https://doi.org/10.1016/j.canlet.2014.07.005

Source records